University of Navarra Clinic
If you are the contact person for this centre and you wish to make any changes, please contact us.
Specialist in Hematology at the Clínica Universidad de Navarra
Researcher in the Solid Tumours Programme at CIMA and the Clínica Universidad de Navarra
Neurologist specialising in the diagnosis and treatment of headaches
Lecturer of the Department of Ophthalmology at the University of Navarra and researcher at the Experimental Ophthalmology Laboratory at the University of Navarra Clinic.
CAR-T cell therapies may, in some cases, produce tumours secondary to treatment. A few months ago, the US Food and Drug Administration (FDA) said it was assessing this risk. Now, a study conducted at Stanford University Medical Center (USA) has tracked 724 patients who received this type of treatment since 2016. Of these, 14 developed another blood tumour, but only one was a T-cell lymphoma that could be a direct consequence of the therapy. Further analysis ruled out this link. The results are published in the journal NEJM.
A multidisciplinary study involving several Spanish research groups has preclinically tested a new type of immunotherapy for multiple myeloma. Instead of modifying T cells to attack the tumour directly, as CAR-T cells do, they have managed to make them secrete bispecific antibodies, which bind to the tumour on one side and to other T cells on the other, attracting them to the tumour. According to the authors, this cell therapy was more effective than traditional CAR-Ts and could generate less resistance. The results are published in the journal Science Translational Medicine.
US researchers have analysed data from 477 people who, using a mobile app, recorded their moods, energy levels and migraine occurrence four times a day for two weeks. Morning attacks were associated with poorer self-rated sleep quality and less energy the day before. Stress and high-energy states were linked to headaches in the afternoon, adds the study, which is published in the journal Neurology.